Athira Pharma, Inc.
ATHA
$0.3848
$0.00481.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -38.20% | -18.87% | -11.00% | -3.42% | -41.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -73.99% | -65.56% | -49.20% | -27.25% | -11.42% |
| Operating Income | 73.99% | 65.56% | 49.20% | 27.25% | 11.42% |
| Income Before Tax | 74.06% | 65.28% | 45.01% | 12.83% | 9.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 74.06% | 65.28% | 45.01% | 12.83% | 9.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 74.06% | 65.28% | 45.01% | 12.83% | 9.25% |
| EBIT | 73.99% | 65.56% | 49.20% | 27.25% | 11.42% |
| EBITDA | 74.63% | 66.14% | 49.59% | 27.44% | 11.50% |
| EPS Basic | 74.54% | 65.92% | 45.87% | 13.87% | 10.16% |
| Normalized Basic EPS | 74.53% | 66.03% | 49.32% | 26.24% | 10.15% |
| EPS Diluted | 74.54% | 65.92% | 45.87% | 13.87% | 10.16% |
| Normalized Diluted EPS | 74.53% | 66.03% | 49.32% | 26.24% | 10.15% |
| Average Basic Shares Outstanding | 1.86% | 1.88% | 1.58% | 1.22% | 1.00% |
| Average Diluted Shares Outstanding | 1.86% | 1.88% | 1.58% | 1.22% | 1.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |